What is Fuse Medical's earnings per share (EPS)?

Fuse Medical (FZMD) reported diluted earnings per share of $0.04 for fiscal year 2022. This represents a 300.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fuse Medical Financials

FZMD

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2023 Currency USD FYE December

This page shows Fuse Medical (FZMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Fuse Medical passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.01x

For every $1 of reported earnings, Fuse Medical generates $0.01 in operating cash flow ($35K OCF vs $3.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.8x

Fuse Medical earns $-4.8 in operating income for every $1 of interest expense (-$815K vs $171K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$18.6M

YoY-8.7%

5Y CAGR-6.7%

Fuse Medical generated $18.6M in revenue in fiscal year 2022. This represents a decrease of 8.7% from the prior year.

EBITDA

-$678K

YoY+68.2%

Fuse Medical's EBITDA was -$678K in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.2% from the prior year.

Net Income

$3.1M

YoY+295.1%

5Y CAGR+34.7%

Fuse Medical reported $3.1M in net income in fiscal year 2022. This represents an increase of 295.1% from the prior year.

EPS (Diluted)

$0.04

YoY+300.0%

5Y CAGR+0.0%

Fuse Medical earned $0.04 per diluted share (EPS) in fiscal year 2022. This represents an increase of 300.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$148K

YoY-73.3%

5Y CAGR-28.7%

10Y CAGR+46.3%

Fuse Medical held $148K in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

74M

YoY+1.4%

5Y CAGR+2.3%

Fuse Medical had 74M shares outstanding in fiscal year 2022. This represents an increase of 1.4% from the prior year.

Margins & Returns

Gross Margin

61.9%

YoY+3.4pp

5Y CAGR+17.1pp

Fuse Medical's gross margin was 61.9% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.

Operating Margin

-4.4%

YoY+6.4pp

5Y CAGR-7.6pp

Fuse Medical's operating margin was -4.4% in fiscal year 2022, reflecting core business profitability. This is up 6.4 percentage points from the prior year.

Net Margin

16.6%

YoY+24.4pp

5Y CAGR+14.0pp

Fuse Medical's net profit margin was 16.6% in fiscal year 2022, showing the share of revenue converted to profit. This is up 24.4 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

FZMD Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$18.6M-8.7%	$20.4M-4.6%	$21.4M-6.6%	$22.9M-13.1%	$26.3M-0.2%	$26.4M
Cost of Revenue	$7.1M-16.2%	$8.5M-2.5%	$8.7M-26.1%	$11.8M-11.9%	$13.4M-8.4%	$14.6M
Gross Profit	$11.5M-3.3%	$11.9M-6.0%	$12.7M+14.1%	$11.1M-14.3%	$13.0M+9.8%	$11.8M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$6.5M-6.8%	$7.0M+7.2%	$6.5M-22.7%	$8.5M0.0%	$8.5M+59.3%	$5.3M
Operating Income	-$815K+62.9%	-$2.2M-113.6%	-$1.0M+76.4%	-$4.3M-122.1%	-$2.0M-328.0%	$859K
Interest Expense	$171K+119.0%	$78K-17.6%	$95K-21.9%	$122K-9.2%	$134K-17.1%	$162K
Income Tax	$24K+33.5%	$18K-6.7%	$19K-97.6%	$781K+301.9%	-$387K-1047.6%	$41K
Net Income	$3.1M+295.1%	-$1.6M-10.8%	-$1.4M+56.8%	-$3.3M-183.8%	$4.0M+465.6%	$700K
EPS (Diluted)	$0.04+300.0%	$-0.020.0%	$-0.02+60.0%	$-0.05-200.0%	$0.05+25.0%	$0.04

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Revenue	$5.0M+25.4%	$4.0M-18.4%	$4.9M+7.7%	$4.5M-2.8%	$4.7M+2.5%	$4.6M-24.8%	$6.1M+42.5%	$4.3M
Cost of Revenue	$1.5M+30.8%	$1.2M-45.8%	$2.2M+45.4%	$1.5M-14.0%	$1.7M-1.1%	$1.7M-31.5%	$2.5M+36.6%	$1.9M
Gross Profit	$3.5M+23.2%	$2.8M+3.1%	$2.7M-10.6%	$3.1M+3.7%	$2.9M+4.8%	$2.8M-20.0%	$3.5M+47.1%	$2.4M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.6M-5.2%	$1.7M+0.6%	$1.7M-0.7%	$1.7M+20.1%	$1.4M-16.8%	$1.7M-14.4%	$2.0M+28.0%	$1.6M
Operating Income	$369K+322.8%	-$166K+55.2%	-$370K-923.6%	$45K+187.0%	-$52K+88.2%	-$439K+33.4%	-$659K+3.3%	-$681K
Interest Expense	$54K-5.5%	$57K+4.3%	$55K+16.7%	$47K+28.7%	$37K+10.8%	$33K+7.5%	$31K+145.1%	$13K
Income Tax	$7K+29.6%	$6K-11.9%	$6K-12.8%	$7K+40.7%	$5K+6.5%	$5K-2.9%	$5K+41.4%	$4K
Net Income	$308K+234.7%	-$228K-105.8%	$3.9M+41768.3%	-$9K+97.1%	-$323K+32.2%	-$476K-35.3%	-$352K+49.5%	-$697K
EPS (Diluted)	N/A	$0.00	N/A	N/A	N/A	$-0.01	N/A	$-0.01

FZMD Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$19.8M+8.0%	$18.3M+5.1%	$17.4M-5.2%	$18.4M-17.1%	$22.2M+15.2%	$19.2M
Current Assets	$13.8M+7.3%	$12.8M+1.6%	$12.6M-11.4%	$14.2M-17.1%	$17.2M-4.8%	$18.0M
Cash & Equivalents	$148K-73.3%	$553K-53.4%	$1.2M+8.0%	$1.1M+30.2%	$844K+4.9%	$805K
Inventory	$9.5M+8.7%	$8.7M+25.1%	$7.0M-11.1%	$7.9M-29.1%	$11.1M+4.2%	$10.6M
Accounts Receivable	$4.0M+13.3%	$3.5M-20.3%	$4.4M-15.7%	$5.2M+0.5%	$5.2M-20.5%	$6.6M
Goodwill	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M-32.1%	$2.9M+254.0%	$821K
Total Liabilities	$20.1M-7.7%	$21.7M+11.3%	$19.5M-0.4%	$19.6M-5.3%	$20.7M-24.0%	$27.2M
Current Liabilities	$12.4M+24.6%	$9.9M+37.2%	$7.2M-8.9%	$8.0M+11.7%	$7.1M-10.8%	$8.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$311K+90.9%	-$3.4M-62.4%	-$2.1M-72.9%	-$1.2M-183.3%	$1.5M+118.4%	-$8.0M
Retained Earnings	-$2.5M+55.2%	-$5.6M-39.4%	-$4.0M-55.2%	-$2.6M-460.2%	$721K	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Total Assets	$19.3M+4.8%	$18.4M-6.7%	$19.8M+3.0%	$19.2M+0.7%	$19.1M+7.2%	$17.8M-2.9%	$18.3M+1.6%	$18.0M
Current Assets	$12.8M+4.7%	$12.2M-11.1%	$13.8M+5.8%	$13.0M0.0%	$13.0M+8.1%	$12.0M-6.1%	$12.8M-0.3%	$12.9M
Cash & Equivalents	$253K+20.1%	$211K+42.7%	$148K-70.8%	$506K-16.2%	$604K+15.6%	$522K-5.6%	$553K-68.7%	$1.8M
Inventory	$9.0M-1.4%	$9.2M-3.6%	$9.5M-3.6%	$9.9M+5.3%	$9.4M+1.0%	$9.3M+6.0%	$8.7M+2.0%	$8.6M
Accounts Receivable	$3.4M+24.4%	$2.8M-30.9%	$4.0M+52.2%	$2.6M-11.4%	$3.0M+37.0%	$2.2M-38.7%	$3.5M+43.5%	$2.5M
Goodwill	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M0.0%	$2.0M
Total Liabilities	$19.5M+3.0%	$19.0M-5.5%	$20.1M-12.9%	$23.1M+0.6%	$22.9M+6.3%	$21.6M-0.9%	$21.7M+2.8%	$21.1M
Current Liabilities	$12.1M+6.9%	$11.3M-8.9%	$12.4M+8.1%	$11.5M+1.2%	$11.3M+16.1%	$9.8M-1.9%	$9.9M+16.8%	$8.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$232K+57.0%	-$539K-73.5%	-$311K+92.0%	-$3.9M+8.1%	-$4.2M-8.2%	-$3.9M-13.5%	-$3.4M-9.8%	-$3.1M
Retained Earnings	-$2.4M+11.2%	-$2.7M-9.1%	-$2.5M+58.6%	-$6.1M-0.2%	-$6.1M-1.6%	-$6.0M-6.4%	-$5.6M-6.7%	-$5.3M

FZMD Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	$35K+102.0%	-$1.8M-851.4%	$237K+5093.8%	-$5K-100.2%	$2.5M+54.6%	$1.6M
Capital Expenditures	N/A	N/A	$21K+35.5%	$15K-63.4%	$42K+105.8%	$20K
Free Cash Flow	N/A	N/A	$216K+1176.4%	-$20K-100.8%	$2.4M+53.9%	$1.6M
Investing Cash Flow	N/A	N/A	-$21K-35.5%	-$15K+85.4%	-$105K-804.5%	-$12K
Financing Cash Flow	-$440K-138.5%	$1.1M+995.6%	-$128K-146.4%	$275K+111.8%	-$2.3M-49.1%	-$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Operating Cash Flow	-$99K-130.0%	$331K+139.8%	-$831K-234.5%	$618K+351.1%	-$246K-149.8%	$494K+124.6%	-$2.0M-3338.4%	$62K
Capital Expenditures	N/A	N/A	N/A	$521K+475.1%	-$139K-200.0%	$139K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	$98K+125.3%	-$385K-208.4%	$355K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$521K-475.1%	$139K+200.0%	-$139K	N/A	N/A
Financing Cash Flow	$142K+152.9%	-$268K-464.2%	-$47K+75.7%	-$196K-159.7%	$328K+162.4%	-$525K-165.8%	$798K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FZMD Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	61.9%+3.4pp	58.5%-0.9pp	59.4%+10.7pp	48.6%-0.7pp	49.3%+4.5pp	44.8%
Operating Margin	-4.4%+6.4pp	-10.8%-5.9pp	-4.8%+14.2pp	-19.0%-11.6pp	-7.4%-10.7pp	3.3%
Net Margin	16.6%+24.4pp	-7.8%-1.1pp	-6.7%+7.8pp	-14.5%-29.5pp	15.0%+12.4pp	2.6%
Return on Equity	N/A	N/A	N/A	N/A	269.8%	N/A
Return on Assets	15.7%+24.3pp	-8.7%-0.5pp	-8.2%+9.8pp	-18.0%-35.9pp	17.8%+14.2pp	3.6%
Current Ratio	1.11-0.2	1.29-0.5	1.74-0.0	1.79-0.6	2.41+0.2	2.26
Debt-to-Equity	-64.58-58.2	-6.33+2.9	-9.24+6.8	-16.04-30.2	14.12+17.5	-3.41
FCF Margin	N/A	N/A	1.0%+1.1pp	-0.1%-9.3pp	9.3%+3.3pp	6.0%

Metric	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21
Gross Margin	69.4%-1.3pp	70.7%+14.8pp	55.9%-11.4pp	67.3%+4.3pp	63.1%+1.4pp	61.7%+3.7pp	58.0%+1.8pp	56.2%
Operating Margin	7.4%+11.5pp	-4.2%+3.4pp	-7.6%-8.6pp	1.0%+2.1pp	-1.1%+8.5pp	-9.6%+1.2pp	-10.9%+5.2pp	-16.0%
Net Margin	6.2%+11.9pp	-5.7%-85.7pp	80.0%+80.2pp	-0.2%+6.7pp	-6.9%+3.5pp	-10.5%-4.7pp	-5.8%+10.6pp	-16.4%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	1.6%+2.8pp	-1.2%-21.0pp	19.8%+19.8pp	-0.1%+1.6pp	-1.7%+1.0pp	-2.7%-0.8pp	-1.9%+1.9pp	-3.9%
Current Ratio	1.06-0.0	1.08-0.0	1.11-0.0	1.14-0.0	1.15-0.1	1.23-0.1	1.29-0.2	1.51
Debt-to-Equity	-84.40-49.2	-35.19+29.4	-64.58-58.6	-5.95-0.5	-5.44+0.1	-5.53+0.8	-6.33+0.4	-6.76
FCF Margin	N/A	N/A	N/A	2.1%+10.4pp	-8.3%-16.1pp	7.8%	N/A	N/A

Note: Shareholder equity is negative (-$311K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Alr Technologies ALRTF

$8.1M

Adm Tronics ADMT

$6.1M

NUGEN MEDICAL DEVICES INC NGMDF

$3.0M

Remsleep Holding RMSL

$10.9M

Stimcell Energetics STME

$7.4M

Frequently Asked Questions

What is Fuse Medical's annual revenue?

Fuse Medical (FZMD) reported $18.6M in total revenue for fiscal year 2022. This represents a -8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fuse Medical's revenue growing?

Fuse Medical (FZMD) revenue declined by 8.7% year-over-year, from $20.4M to $18.6M in fiscal year 2022.

Is Fuse Medical profitable?

Yes, Fuse Medical (FZMD) reported a net income of $3.1M in fiscal year 2022, with a net profit margin of 16.6%.

What is Fuse Medical's EBITDA?

Fuse Medical (FZMD) had EBITDA of -$678K in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

What is Fuse Medical's gross margin?

Fuse Medical (FZMD) had a gross margin of 61.9% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fuse Medical's operating margin?

Fuse Medical (FZMD) had an operating margin of -4.4% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is Fuse Medical's net profit margin?

Fuse Medical (FZMD) had a net profit margin of 16.6% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

What is Fuse Medical's operating cash flow?

Fuse Medical (FZMD) generated $35K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Fuse Medical's total assets?

Fuse Medical (FZMD) had $19.8M in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does Fuse Medical have outstanding?

Fuse Medical (FZMD) had 74M shares outstanding as of fiscal year 2022.

What is Fuse Medical's current ratio?

Fuse Medical (FZMD) had a current ratio of 1.11 as of fiscal year 2022, which is considered adequate.

What is Fuse Medical's debt-to-equity ratio?

Fuse Medical (FZMD) had a debt-to-equity ratio of -64.58 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fuse Medical's return on assets (ROA)?

Fuse Medical (FZMD) had a return on assets of 15.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

Why is Fuse Medical's debt-to-equity ratio negative or unusual?

Fuse Medical (FZMD) has negative shareholder equity of -$311K as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Fuse Medical's Piotroski F-Score?

Fuse Medical (FZMD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fuse Medical's earnings high quality?

Fuse Medical (FZMD) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fuse Medical cover its interest payments?

Fuse Medical (FZMD) has an interest coverage ratio of -4.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.